Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression

European Journal of Cancer

Volumn 42, Issue 10, 2006, Pages 1369-1379

  Mieog, J Sven D ^a   van der Hage, Jos A ^a   van de Vijver, Marc J ^b   van de Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Anthracycline; Breast cancer; Clinical tumour response; p53; Pathological complete response; Predictive markers; Preoperative chemotherapy; Prognostic markers

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TAMOXIFEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONFIDENCE INTERVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746891199     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.054     Document Type: Article

References (48)

1. van der Hage J.A., van de Velde C.J., Julien J.P., Tubiana-Hulin M., Vandervelden C., and Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19 22 (2001) 4224-4237
2. Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
3. Bonadonna G., Valagussa P., Brambilla C., Ferrari L., Moliterni A., Terenziani M., et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16 1 (1998) 93-100
4. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 2 (1999) 460-469
5. Chollet P., Amat S., Cure H., de Latour M., Le Bouedec G., Mouret-Reynier M.A., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86 7 (2002) 1041-1046
6. Fisher B., and Mamounas E.P. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13 3 (1995) 537-540
7. Charfare H., Limongelli S., and Purushotham A.D. Neoadjuvant chemotherapy in breast cancer. Br J Surg 92 1 (2005) 14-23
8. Hamilton A., and Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11 6 (2000) 647-663
9. Makris A., Powles T.J., Allred D.C., Ashley S.E., Trott P.A., Ormerod M.G., et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53 1 (1999) 51-59
10. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., and van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88 3 (2003) 406-412
11. Hayward J.L., Carbone P.P., Heuson J.C., Kumaoka S., Segaloff A., and Rubens R.D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39 3 (1977) 1289-1294
12. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 5 (1991) 403-410
13. van Slooten H.J., Clahsen P.C., van Dierendonck J.H., Duval C., Pallud C., Mandard A.M., et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 74 1 (1996) 78-85
14. Clahsen P.C., van de Velde C.J., Duval C., Pallud C., Mandard A.M., Delobelle-Deroide A., et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16 2 (1998) 470-479
15. van de Vijver M.J., Peterse J.L., Mooi W.J., Wisman P., Lomans J., Dalesio O., et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319 19 (1988) 1239-1245
16. Semiglazov V.F., Topuzov E.E., Bavli J.L., Moiseyenko V.M., Ivanova O.A., Seleznev I.K., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5 7 (1994) 591-595
17. Cleator S.J., Makris A., Ashley S.E., Lal R., and Powles T.J. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 16 2 (2005) 267-272
18. Gianni L., Baselga J., Eiermann W., Guillem Porta V., Semiglazov V., Lluch A., et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol (Meeting Abstracts) 23 16_suppl (2005) 513
19. Abraham D.C., Jones R.C., Jones S.E., Cheek J.H., Peters G.N., Knox S.M., et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78 1 (1996) 91-100
20. Segel M.C., Paulus D.D., and Hortobagyi G.N. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 169 1 (1988) 49-54
21. Veronesi U., Bonadonna G., Zurrida S., Galimberti V., Greco M., Brambilla C., et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222 5 (1995) 612-618
22. Vinnicombe S.J., MacVicar A.D., Guy R.L., Sloane J.P., Powles T.J., Knee G., et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198 2 (1996) 333-340
23. Pharoah P.D., Day N.E., and Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80 12 (1999) 1968-1973
24. Thor A.D., Moore II D.H., Edgerton S.M., Kawasaki E.S., Reihsaus E., Lynch H.T., et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84 11 (1992) 845-855
25. Allred D.C., Clark G.M., Elledge R., Fuqua S.A., Brown R.W., Chamness G.C., et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85 3 (1993) 200-206
26. Yamashita H., Nishio M., Toyama T., Sugiura H., Zhang Z., Kobayashi S., et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6 1 (2004) R24-R30
27. Makris A., Powles T.J., Dowsett M., Osborne C.K., Trott P.A., Fernando I.N., et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3 4 (1997) 593-600
28. MacGrogan G., Mauriac L., Durand M., Bonichon F., Trojani M., de M., et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74 9 (1996) 1458-1465
29. Niskanen E., Blomqvist C., Franssila K., Hietanen P., and Wasenius V.M. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76 7 (1997) 917-922
30. Rozan S., Vincent-Salomon A., Zafrani B., Validire P., De Cremoux P., Bernoux A., et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79 1 (1998) 27-33
31. Mathieu M.C., Koscielny S., Le Bihan M.L., Spielmann M., and Arriagada R. p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group. Lancet 345 8958 (1995) 1182
32. Jarvinen T.A., Holli K., Kuukasjarvi T., and Isola J.J. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77 12 (1998) 2267-2273
33. Kandioler-Eckersberger D., Ludwig C., Rudas M., Kappel S., Janschek E., Wenzel C., et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6 1 (2000) 50-56
34. Geisler S., Lonning P.E., Aas T., Johnsen H., Fluge O., Haugen D.F., et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61 6 (2001) 2505-2512
35. Berns E.M., Foekens J.A., Vossen R., Look M.P., Devilee P., Henzen-Logmans S.C., et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60 8 (2000) 2155-2162
36. Colleoni M., Orvieto E., Nole F., Orlando L., Minchella I., Viale G., et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35 4 (1999) 574-579
37. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124 7 (2000) 966-978
38. Pierga J.Y., Mouret E., Dieras V., Laurence V., Beuzeboc P., Dorval T., et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83 11 (2000) 1480-1487
39. Botti C., Vici P., Lopez M., Scinto A.F., Cognetti F., and Cavaliere R. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 181 3 (1995) 202-208
40. Rouzier R., Extra J.M., Klijanienko J., Falcou M.C., Asselain B., Vincent-Salomon A., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20 5 (2002) 1304-1310
41. Deurloo E.E., Tanis P.J., Gilhuijs K.G., Muller S.H., Kroger R., Peterse J.L., et al. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer 39 8 (2003) 1068-1073
42. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 9381 (2003) 362-369
43. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 12 (2004) 2284-2293
44. Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., et al. Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. J Clin Oncol (2005)
45. Hannemann J., Oosterkamp H.M., Bosch C.A., Velds A., Wessels L.F., Loo C., et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 20;23 15 (2005) 3331-3342
46. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19(3):602-611.
47. Rutgers E.J., Meijnen P., and Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 6 4 (2004) 165-169
48. Farmer P., Iggo R., Becette V., Tubiana-Hulin M., Fumoleau P., Piccart M.J., et al. High quality gene expression microarray data from a multicentre prospective trial: results of the first microarray analysis in the EORTC 10994/BIG 00-01 study. European Journal of Cancer Supplements 2 3 (2004) 99